Are you Dr. Pandya?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 70 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
Beth Israel Deaconess Medical Center
330 Brookline Avenue
Boston, MA 02215Phone+1 617-975-5000
Summary
- Dr. Shuchi Pandya, MD is an oncologist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts. She is affiliated with Beth Israel Deaconess Medical Center and is an Instructor in Medicine at Beth Israel Deaconess Medical Center.
Education & Training
- Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2003 - 2006
- Tufts University School of MedicineClass of 2003
Certifications & Licensure
- MA State Medical License 2006 - 2026
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Publications & Presentations
PubMed
- 2 citationsPharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study.Bin Fan, Ghassan K Abou-Alfa, Andrew X Zhu, Shuchi S Pandya, Hongxia Jia
Cancer Chemotherapy and Pharmacology. 2024-05-01 - 1 citationsSafety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study.Courtney D DiNardo, Stéphane De Botton, Daniel A Pollyea, Richard M Stone, Jessica K Altman
American Journal of Hematology. 2023-09-01 - 9 citationsVolumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of Ivosidenib.Benjamin M. Ellingson, Grace Kim, Matthew S. Brown, Jihey Lee, Noriko Salamon
Neuro-Oncology. 2021-11-09